Nano-sized carriers in gene therapy for renal fibrosis in vivo. (1st January 2017)

• Record Type: Journal Article
• Authors: Miyazawa, Haruhisa; Hirai, Keiji; Ookawara, Susumu; Ishibashi, Kenichi; Morishita, Yoshiyuki
• Is Part Of: Nano reviews & experiments. Volume 8(2017)
• Publication Date: 2017-01-01
• Subjects: Renal fibrosis -- gene therapy -- nano-sized carriers -- viral vector -- non-viral vector; Nanoscience -- Periodicals; Nanotechnology -- Periodicals; Nanobiotechnology -- Periodicals; Nanobiotechnology; Nanoscience; Nanotechnology; Nanotechnology; Periodicals; Electronic journals; Fulltext; Internet Resources; Periodicals; 620.5
• DOI: 10.1080/20022727.2017.1331099
• Languages: English
• ISSNs: 2002-2727

Abstract

ABSTRACT: Renal fibrosis is the final common pathway leading to end-stage renal failure regardless of underlying initial nephropathies. No specific therapy has been established for renal fibrosis. Gene therapy is a promising strategy for the treatment of renal fibrosis. Nano-sized carriers including viral vectors and non-viral vectors have been shown to enhance the delivery and treatment effects of gene therapy for renal fibrosis in vivo . This review focuses on the mechanisms of renal fibrosis and the in vivo technologies and methodologies of nano-sized carriers in gene therapy for renal fibrosis. RESPONSIBLE EDITOR Alexander Seifalian Director of Nanotechnology & Regenerative Medicine Ltd., The London BioScience Innovation Centre, London, UNITED KINGDOM